CFM
IMA

Catalyst Funds Management’s ImageneBio Inc IMA Stock Holding History

Catalyst Funds Management’s Portfolio IMA Stock Details IMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-375
Closed -$7.79K – 778
2024
Q3 		$7.79K Hold
375
– – ﹤0.01% 1216
2024
Q2 		$7.42K Buy
+375
New +$6.62K ﹤0.01% 985

Other funds holding IMA

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Catalyst Funds Management's IMA Position: Q4 2024 in Review

Catalyst Funds Management sold out of ImageneBio Inc (IMA) in Q4 2024, closing a stake of 375 shares — an estimated $7.79K sold.

Catalyst Funds Management first reported a position in IMA in Q2 2024 and held it in 2 quarters. The position peaked at $7.79K in Q3 2024. 52 funds tracked by Wall St. Rank hold IMA as of Q4 2024.

  • Catalyst Funds Management reported no remaining ImageneBio Inc position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 375 ImageneBio Inc shares in Q4 2024, an estimated $7.79K.
  • Catalyst Funds Management first reported a position in ImageneBio Inc in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's ImageneBio Inc position peaked at $7.79K in Q3 2024.
  • 52 funds tracked by Wall St. Rank held ImageneBio Inc as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.